Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin alfa to reduce top-up transfusions in neonates with hemolytic disease after intrauterine transfusions
NL-OMON50421Phase 3Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2017
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of darbepoetin alfa in Erythroblastosis fetalis (HDFN) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Number of top-up transfusions required per infant. Started Oct 2017; status: active, not recruiting.
02
Drugs
darbepoetin alfa
03
Conditions
Erythroblastosis fetalis (HDFN)
Beyond the preview
Go deeper on NL-OMON50421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50421.